Cargando…
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
BACKGROUND: Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction. Identification of patients at lower bleeding risk is important in selecting patients who are likely to derive more favorable outcomes versus risk from this strategy. METHODS AND RESULTS:...
Autores principales: | Magnani, Giulia, Ardissino, Diego, Im, KyungAh, Budaj, Andrzej, Storey, Robert F., Steg, P. Gabriel, Bhatt, Deepak L., Cohen, Marc, Oude Ophius, Ton, Goudev, Assen, Parkhomenko, Alexander, Kamensky, Gabriel, Angiolillo, Dominick J., López‐Sendón, José, Johanson, Per, Braunwald, Eugene, Sabatine, Marc S., Bonaca, Marc P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955333/ https://www.ncbi.nlm.nih.gov/pubmed/33559485 http://dx.doi.org/10.1161/JAHA.120.017008 |
Ejemplares similares
-
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018) -
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019) -
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021) -
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial
por: Furtado, Remo H. M., et al.
Publicado: (2020) -
Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)